33 , 34 Another study found an increased risk of bleeding in patients with MPNs treated with P2Y12 inhibitor, although it did not reach statistical significance (OR: 2.829; 95% CI: 0.998-8.021). 35 The efficacy of dual antiplatelet therapy for post-AMI therapy and the risk of bleeding events has not been characterized and therefore remains an unanswered question.
← all excerpts
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction: Insights From National Inpatient Sample.
1
—
—